Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

UnitedHealth Reports Q1 Earnings – Raises 2021 Earnings Guidance

By John F. Heerdink, Jr.

UnitedHealth Group Incorporated (UNH) reported strong Q1 earnings, raising prior earning guidance for full-year 2021. The adjusted earnings per share increased 42.7% to $5.31. Revenue increased 9% to $70.2 billion, driven by 11% growth in revenue for the Optum health services division to $36.4 billion.

“The unique combined capabilities of Optum and UnitedHealthcare and the unwavering commitment of our people continue to help advance the way care is delivered, improving results for those we serve and shareholders,” stated UnitedHealth CEO, Andrew Witty.

Medicare Advantage customers increased 635,000 from Q4 to a total of 6.335 million. Medicaid members also increased 355,000 to 6.975 million. Commercial insurance members under UnitedHealth rose 95,000 to 26.315 million. The company informed that the medical costs as a percentage of premiums remained in check, with its medical care ratio dipping to 80.9% from 81% a year ago.

The company raised its 2021 guidance for full-year with adjusted EPS to a range of $18.10-$18.60 from earlier $17.75 to $18.25. United Health did not alter its earlier estimates that the COVID-related expenses and deferred care could reduce $1.80 per share from EPS this year.

Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. To learn more about (UNH) please visit the Vista Partners Company Dedicated UNH Coverage Page

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: UnitedHealth Crushes Earnings; Dow Jones Stock Clears New Entry in Investor's Business Daily)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us